ELTX
NASDAQElicio Therapeutics Inc.
Elicio Therapeutics Inc. (ELTX) is a Biotechnology: Pharmaceutical Preparations company listed on NASDAQ. In the last 30 days Quantisnow tracked 3 wire items for ELTX, including 2 press releases and news items and 1 SEC filing. The most recent was published Oct 29, 2026.
News · 26 weeks39-33%
2026-05-102026-11-01
Mix1890d
- Insider7(39%)
- Other6(33%)
- SEC Filings4(22%)
- Offering1(6%)
Latest news
25 items- PRElicio Therapeutics to Present Phase 2 AMPLIFY-7P Results at the SITC 2026 Annual MeetingKeynote/plenary session and late-breaking poster presentation highlight additional data from Phase 2 AMPLIFY-7P trial of camupepimut (ELI-002 7P) in KRAS-mutated pancreatic cancerAdditional preclinical poster presentation showcases an expanded application of the AMP-platform in an antigen-agnostic intratumoral treatment approach BOSTON, Oct. 29, 2026 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (NASDAQ:ELTX) ("Elicio" or the "Company"), a clinical-stage biotechnology company developing next-generation immunotherapies for KRAS-driven cancers, today announced that the Company will conduct a keynote/plenary presentation, as well as two poster presentations showcasing additional results from
- PRElicio Therapeutics Presents Late-Breaking Phase 2 AMPLIFY-7P Results at ESMO Congress 2026 and Announces Simultaneous Publication in Nature MedicineMultiple pre-specified subgroup analyses favored camupepimut (ELI-002 7P), including patients with and without detectable baseline ctDNA.Encouraging disease-free survival outcomes were observed in both ctDNA-negative (HR 0.51) and ctDNA-positive (HR 0.57) patients.Baseline prognostic imbalances provide important context for the intent-to-treat results, including a 53% lower risk of recurrence or death with camupepimut (multivariable adjusted HR 0.47; p=0.0086).Integrated clinical and translational findings provide clear direction for refining patient stratification, optimizing dosing and advancing Phase 3 development. BOSTON, Oct. 23, 2026 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (NA
- SECSEC Form DEF 14A filed by Elicio Therapeutics Inc.DEF 14A - Elicio Therapeutics, Inc. (0001601485) (Filer)
- PRElicio Therapeutics Announces Late-Breaking Phase 2 AMPLIFY-7P Data Selected for Proffered Paper Oral Presentation at ESMO Congress 2026New pre-specified analyses from the randomized Phase 2 study will further characterize the clinical potential of ELI-002 7P (camupepimut) in adjuvant pancreatic cancerFindings are expected to inform a refined Phase 3 development strategy BOSTON, Sept. 24, 2026 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (NASDAQ:ELTX) ("Elicio" or the "Company"), a clinical-stage biotechnology company developing next-generation immunotherapies for KRAS-driven cancers, today announced that new pre-specified analyses from the randomized Phase 2 AMPLIFY-7P study of ELI-002 7P in resected pancreatic ductal adenocarcinoma ("PDAC") have been selected for a late-breaking Proffered Paper oral presentation at the
- SECElicio Therapeutics Inc. filed SEC Form 8-K: Shareholder Director Nominations, Other Events8-K - Elicio Therapeutics, Inc. (0001601485) (Filer)
- INSIDERSEC Form 4 filed by Director Adams Julian4 - Elicio Therapeutics, Inc. (0001601485) (Issuer)
- INSIDERSEC Form 4 filed by Director Ashe Carol Gail4 - Elicio Therapeutics, Inc. (0001601485) (Issuer)
- INSIDERSEC Form 4 filed by Director Chudnovsky Yekaterina4 - Elicio Therapeutics, Inc. (0001601485) (Issuer)
- INSIDERSEC Form 4 filed by Director Nissenson Allen4 - Elicio Therapeutics, Inc. (0001601485) (Issuer)
- INSIDERSEC Form 4 filed by Director Ruffolo Robert R4 - Elicio Therapeutics, Inc. (0001601485) (Issuer)
- INSIDERSEC Form 4 filed by Director Wilson Karen J4 - Elicio Therapeutics, Inc. (0001601485) (Issuer)
- INSIDERSEC Form 4 filed by Director Venkatesan Jay4 - Elicio Therapeutics, Inc. (0001601485) (Issuer)
- PRElicio Therapeutics to Participate at the H.C. Wainwright 28th Annual Global Investment ConferenceBOSTON, Aug. 31, 2026 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (NASDAQ:ELTX, "Elicio" or the "Company")), a clinical-stage biotechnology company developing next-generation immunotherapies for KRAS-driven cancers, today announced that Robert Connelly, Chief Executive Officer and Pete DeMuth, PhD, Chief Scientific Officer, will participate in a fireside chat at the upcoming H.C. Wainwright 28th Annual Global Investment Conference, taking place September 14-16, 2026, in New York, New York. H.C. Wainwright 28th Annual Global Investment Conference Format: Fireside ChatDate: Monday, September 14, 2026Time: 2:00 PM ET The live webcast and replay of the presentation will be available here a
- PRElicio Therapeutics to Participate at the Wells Fargo 21st Annual Healthcare ConferenceBOSTON, Aug. 24, 2026 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (NASDAQ:ELTX, "Elicio" or the "Company")), a clinical-stage biotechnology company developing next-generation immunotherapies for KRAS-driven cancers, today announced that management will participate in one-on-one meetings at the upcoming Wells Fargo 21st Annual Healthcare Conference, taking place September 8-10, 2026, in Boston, MA. Wells Fargo 21st Annual Healthcare ConferenceFormat: One-on-one MeetingsDate: Thursday, September 10, 2026 If you are interested in arranging a 1×1 meeting with management at the conference, please contact your Wells Fargo representative. About Elicio Therapeutics Elicio Therapeutics, Inc.
- SECSEC Form 10-Q filed by Elicio Therapeutics Inc.10-Q - Elicio Therapeutics, Inc. (0001601485) (Filer)
- SECElicio Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Elicio Therapeutics, Inc. (0001601485) (Filer)
- PRElicio Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate UpdatesFollowing the observation of multiple complete responses, Elicio plans to initiate a Phase 1 combination study of ELI-002 7P plus a RAS small molecule inhibitor with or without an anti-PD-1 inhibitor in metastatic pancreatic cancer; Phase 1 study anticipated to initiate Q4 2026 While Phase 2 AMPLIFY-7P trial did not meet its primary endpoint, Elicio continues to evaluate pre-specified subgroups, including the R0 resected population, to further refine its Phase 3 development strategy for ELI-002 7P in adjuvant pancreatic ductal adenocarcinoma ("PDAC")Memorial Sloan Kettering Cancer Center-led Phase 1 trial activated evaluating ELI-002 7P plus chemotherapy and checkpoint inhibition with treat
- PRElicio Therapeutics Announces Activation of the Investigator-Initiated Phase 1 Study of Neoadjuvant ELI-002 7P for Pancreatic Ductal AdenocarcinomaPhase 1 study conducted by Memorial Sloan Kettering ("MSK") Cancer Center and funded by The Lustgarten FoundationStudy to evaluate ELI-002 7P in combination with chemotherapy and checkpoint inhibition in the neoadjuvant settingExpected to enroll 20 patients with resectable or borderline resectable pancreatic ductal adenocarcinoma ("PDAC") BOSTON, Aug. 10, 2026 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (NASDAQ:ELTX) ("Elicio" or the "Company"), a clinical-stage biotechnology company developing next-generation immunotherapies for KRAS-driven cancers, today announced the opening of the investigator-initiated ("IIT") Phase 1 neoadjuvant study (NCT07671339) evaluating ELI-002 7P in combin
- INSIDERSEC Form 4 filed by Officer Haqq Christopher4 - Elicio Therapeutics, Inc. (0001601485) (Issuer)
- INSIDERSEC Form 4 filed by Chief Scientific Officer Demuth Peter4 - Elicio Therapeutics, Inc. (0001601485) (Issuer)
- INSIDERSEC Form 4 filed by CEO, President and Director Connelly Robert4 - Elicio Therapeutics, Inc. (0001601485) (Issuer)
- INSIDERSEC Form 4 filed by Officer Shah Preetam4 - Elicio Therapeutics, Inc. (0001601485) (Issuer)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Elicio Therapeutics Inc.SCHEDULE 13G/A - Elicio Therapeutics, Inc. (0001601485) (Subject)
- PRElicio Therapeutics Announces Closing of $15 Million Registered Direct OfferingBOSTON, July 06, 2026 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (NASDAQ:ELTX) ("Elicio" or the "Company"), a clinical-stage biotechnology company developing next-generation immunotherapies for KRAS-driven cancers, today announced the closing of its previously announced registered direct offering (the "Offering") pursuant to a definitive securities purchase agreement led by two new fundamental institutional investors with participation from a large existing shareholder for the purchase of an aggregate of 4,380,313 shares of its common stock. The gross proceeds to the Company were approximately $15 million, before deducting placement agents’ fees and other Offering expenses. Elicio inten
- SECSEC Form 424B5 filed by Elicio Therapeutics Inc.424B5 - Elicio Therapeutics, Inc. (0001601485) (Filer)
ELTX FAQ
7 questionsWhat is the latest news on ELTX?
In the last 30 days Quantisnow tracked 3 wire items for ELTX: 2 press releases and news items and 1 SEC filing. The most recent was published on October 29, 2026.Where does ELTX stock trade?
Elicio Therapeutics Inc. (ELTX) is listed on NASDAQ.What sector and industry is ELTX in?
Elicio Therapeutics Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Elicio Therapeutics Inc. go public?
Elicio Therapeutics Inc. (ELTX) completed its IPO in 2021.What are analysts saying about ELTX?
Elicio Therapeutics Inc. has had 4 recent analyst actions on file. The most recent action was from Ladenburg Thalmann: Buy with a $12.00 price target on 2026-06-18. Recent price targets range from $12.00 to $27.00.What companies are similar to ELTX?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.), NVS (Novartis AG). Compare ELTX side-by-side with any of them on Quantisnow.How can I track ELTX on Quantisnow?
Quantisnow aggregates Elicio Therapeutics Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow ELTX to receive live email and push alerts on every new disclosure.